Web Exclusives

Shortages, inventory management, and challenges of in-home care were just a few of the topics in AVBCC’s wide-ranging webinar on how COVID-19 is affecting oncology pharmacy. Read Article ›

As the COVID-19 pandemic stretches into its fifth month in the United States, advocacy groups providing support for patients with cancer are delivering essential support and services, while they worry about the long-term psychosocial impact on these patients and the future of clinical trials. Read Article ›

In a phase 2 study of women with recurrent platinum-sensitive ovarian cancer, safety and efficacy end points favored the combination of niraparib and bevacizumab over niraparib monotherapy. Read Article ›

New study findings represent a significant advance for women with BRCA-related relapsed ovarian cancer responding to platinum-based chemotherapy. Read Article ›

In the PRIMA study, patients with recurrent ovarian cancer receiving maintenance therapy with an individualized dose of niraparib had similar efficacy compared with placebo as patients receiving a fixed dose of niraparib while experiencing half as many thrombocytopenic events. Read Article ›

In a pooled analysis of 2 randomized trials of rucaparib for the treatment of patients with recurrent high-grade ovarian cancer, deleterious BRCA mutations were identified in 71% of patients with responses lasting at least 1 year but in only 52% of short-term responders. Read Article ›

In a study of 76 English-speaking women with newly diagnosed ovarian cancer who underwent genetic testing, those found to have a pathogenic mutation did not report increased levels of stress, anxiety, or depression compared with pre-genetic testing. Those testing negative for mutations saw their posttest anxiety levels decline. Read Article ›

As we learn more about the complicated behavior of the COVID-19 virus, we have come to understand that overactivation of the patient’s own immune system can often be the most dangerous factor. In this webcast, top cancer experts discuss the latest studies investigating using anti-cancer therapies as treatments for COVID-19. What are some of the options and where does the research stand today? Read Article ›

The COVID-19 pandemic has led to the elimination of several restrictions on telehealth and infusion therapy in the home setting. In this webcast, a panel of experts discuss the short- and long-term prospects for in-home infusion for patients with cancer. What are the benefits and drawbacks? Read Article ›

Results from the phase 3 ARIEL3 clinical trial showed that maintenance therapy with rucaparib leads to significantly improved progression-free survival in patients with advanced ovarian cancer and non-BRCA homologous recombinant repair gene mutations. Read Article ›

At the 12-month landmark analysis of the single-arm phase 2 OVARIO clinical trial, 75% of patients in the overall population of patients with newly diagnosed stage IIIB-IV ovarian cancer remained progression-free. Read Article ›

Data from the phase 3 PAOLO-1 clinical trial showed that progression-free survival was significantly increased with olaparib plus bevacizumab as maintenance therapy. Read Article ›

Page 3 of 12

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: